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Abstract
Introduction
Although HIV infection and its associated co-morbidities remain the commonest reason for
hospitalisation in Africa, their impact on economic costs and health-related quality of life
(HRQoL) are not well understood. This information is essential for decision-makers to make
informed choices about how to best scale-up anti-retroviral treatment (ART) programmes.
This study aimed to quantify the impact of HIV infection and ART on economic outcomes in
a prospective cohort of hospitalised patients with high HIV prevalence.
Methods
Sequential medical admissions to Queen Elizabeth Central Hospital, Malawi, between
June-December 2014 were followed until discharge, with standardised classification of med-
ical diagnosis and estimation of healthcare resources used. Primary costing studies esti-
mated total health provider cost by medical diagnosis. Participants were interviewed to
establish direct non-medical and indirect costs. Costs were adjusted to 2014 US$ and INT$.
HRQoL was measured using the EuroQol EQ-5D. Multivariable analyses estimated predic-
tors of economic outcomes.
Results
Of 892 eligible participants, 80.4% (647/892) were recruited and medical notes found. In
total, 447/647 (69.1%) participants were HIV-positive, 339/447 (75.8%) were on ART prior
to admission, and 134/647 (20.7%) died in hospital. Mean duration of admission for HIV-
positive participants not on ART and HIV-positive participants on ART was 15.0 days (95%
CI: 12.0–18.0) and 12.2 days (95%CI: 10.8–13.7) respectively, compared to 10.8 days
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(95%CI: 8.8–12.8) for HIV-negative participants. Mean total provider cost per hospital
admission was US$74.78 (bootstrap 95%CI: US$25.41-US$124.15) higher for HIV-positive
than HIV-negative participants. Amongst HIV-positive participants, the mean total provider
cost was US$106.87 (bootstrap 95%CI: US$25.09-US$106.87) lower for those on ART
than for those not on ART. The mean total direct non-medical and indirect cost per hospital
admission was US$87.84. EQ-5D utility scores were lower amongst HIV-positive partici-
pants, but not significantly different between those on and not on ART.
Conclusions
HIV-related hospital care poses substantial financial burdens on health systems and
patients; however, per-admission costs are substantially lower for those already initiated
onto ART prior to admission. These potential cost savings could offset some of the addi-
tional resources needed to provide universal access to ART.
Introduction
In Eastern and Southern Africa, HIV infection and its associated co-morbidities remain the
most common reasons for hospitalisation [1–3]. Up to three quarters of adults admitted for
medical reasons are HIV-positive [2], with little change observed since the scale-up of anti-ret-
roviral treatment (ART) began [4, 5]. Hospitals account for a major proportion of health
expenditure in the region [6] and reducing the need for hospital care could lead to major cost
savings for health systems. However, without a clear understanding of the costs of providing
hospital care for people living with HIV, and how this changes with ART [7], decision-makers
across the region are unable to include these potential cost savings in assessments of the cost of
scaling up ART.
In resource-rich countries, timely initiation of ART in HIV-positive individuals has sub-
stantially reduced the need for hospital care and, consequently, the costs of providing HIV
care [8, 9]. In Africa, initiation of ART reduces rates and duration of hospitalisations in HIV-
positive individuals by up to 70% [10–12], but the degree to which this translates into cost
savings for healthcare providers is still uncertain [7]. Timely initiation of ART reduces the
risk of opportunistic and TB disease [13], but HIV-positive individuals on ART may still
need hospital care, and individuals may incur greater costs during their hospitalisation than
those not receiving ART, possibly as a consequence of developing immune constitution syn-
drome (IRS) [11, 14]. As we move towards immediate initiation of ART for HIV-positive
individuals [15], the combined reduction in the risk of developing TB, IRS and other oppor-
tunistic illnesses may translate into cost savings. Understanding the impact of timely initia-
tion of ART on the wider health system, especially hospital care, will be essential for
budgetary and service planning, and for informing economic evaluations of HIV prevention
and treatment interventions.
In this study, we recruited a cohort of adults admitted to the medical wards at Queen Eliza-
beth Hospital in Blantyre, Malawi. The main aim was to quantify the impact of HIV infection
and ART on economic outcomes for adults admitted to these medical wards.
Costs and QoL outcomes of hospitalisation
PLOS ONE | https://doi.org/10.1371/journal.pone.0192991 March 15, 2018 2 / 21
necessarily those of the Wellcome Trust, the NHS,
the NIHR or the Department of Health. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: All authors declare that they
have no competing interests.
Methods
Study design and participants
We undertook a prospective cohort study in Queen Elizabeth Central Hospital (QECH), Blan-
tyre, Malawi, between June and December 2014. We collected medical diagnosis and resource
use data, and undertook primary resource-based costing studies to estimate health provider
costs. We also investigated the costs incurred by patients and their families as a result of hospi-
talisation, and evaluated their health-related quality of life (HRQoL) on admission and at regu-
lar time intervals thereafter.
QECH is the largest hospital in Malawi, with approximately 1,500 beds and 25,000 adult
admissions per year, and an HIV prevalence of approximately 70% amongst medical inpatients
[16]. The hospital has a large emergency department where all new patients are triaged and
assessed by medical doctors or clinical officers. Clinicians make a preliminary medical diagno-
sis, and those in need of admission are transferred to one of three medical wards (Male Medi-
cal; Female Medical; TB Ward).
Systematic recruitment was used to select every fifth adult (age  18 years) admission
from each of the three ward registers, together with all adults diagnosed with an AIDS
defining illness on admission. Participants were approached for informed consent on the
first working day after admission. Participants too sick to provide consent were reviewed
daily.
A structured questionnaire was used to collect data on the first working day after admis-
sion, including socio-demographic data, direct non-medical costs and indirect costs associated
with the admission, and health-related quality of life (HRQoL) outcomes. Follow-up question-
naires were administered to participants every three to seven days thereafter, and recorded
direct non-medical and indirect costs for the preceding day, and HRQoL on the day of assess-
ment. After discharge or death, a trained study doctor extracted data from the medical notes
and drug charts. Primary costing studies were undertaken to estimate direct health provider
costs of each hospital admission episode [17, 18].
Ethical approval was obtained from the College of Medicine Ethics Review Committee
(P.08/12/1272), University of Malawi, and the University of Warwick Biomedical Research
Ethics Committee (REGO-2013-061). All participants provided written (or witnessed thumb-
print if illiterate) informed consent.
Medical diagnosis and resource-use
Data extraction tools and codebooks were developed and piloted to extract the following data
from the medical notes: primary medical diagnosis upon discharge or death, HIV status, anti-
retroviral drug use, duration of hospital admission, types and numbers of investigations and
procedures performed, medications given, and the participant’s outcome (discharged; trans-
ferred to another hospital; or died). Coding of the final medical diagnosis upon discharge or
death was based on International Classification of Diseases, 9th Revision, Clinical Modifica-
tion (ICD-9-CM) [19]. Only the primary medical diagnosis that necessitated hospital admis-
sion was recorded.
During this study, Malawian national guidelines recommended HIV testing and counsel-
ling for all individuals attending or admitted to a health facility, and ART to those who meet
eligibility criteria (CD4 count<350 cells/μl; WHO stage 3 or 4; breastfeeding or pregnant).
Since August 2016, Malawi has been offering ART to all HIV-positive individuals irrespective
of HIV disease stage.
Costs and QoL outcomes of hospitalisation
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Direct health provider cost
We identified a list of medical resource inputs (e.g. days of admission; full blood count) from
the medical data extracted by the doctors, and then undertook accounting studies to estimate
the unit costs for each resource input, and subsequently the total direct health provider cost.
For each resource input, we included the cost of: staff salaries; training of staff; consumables
and equipment; monitoring and evaluation; and associated overheads. S1 Text provides a
detailed description of the costing processes, and how the total direct health provider cost was
estimated. The international market price was used for the cost of drugs [20].
Direct non-medical and indirect cost
The development, language translations and pilot testing of participant questionnaires fol-
lowed previous procedures [21], with a detailed description provided in S2 Text. The total
direct non-medical and indirect cost per participant was estimated for the duration of the hos-
pital admission. This included costs incurred by the participant and their main family mem-
ber/carer who stayed with them during their hospital admission. The total direct non-medical
and indirect cost was estimated by adding the costs on the day of admission, to the average
daily cost for each subsequent period between interviews multiplied by the duration of each
subsequent period.
The direct non-medical costs included the cost of transportation, food, drinks, toiletries,
clothing and other items bought during the hospital admission. For indirect costs, we recorded
whether participants or their carers had taken time off work, and if so, the amount of time,
and multiplied this by their self-reported income [22]. For self-reported income, we asked par-
ticipants their average weekly earnings from formal and informal employment, and divided by
the average number of days worked per week to estimate average income per day worked.
User fees are not charged for care in the hospital, but hospital inpatients may still incur costs
of purchasing medications through private providers if there are issues with stocks at the hos-
pital. Participants in this study did not report incurring any such costs.
Health-related quality of life
The Chichewa version of the EuroQoL EQ-5D-3L [23] was used to assess HRQoL of partici-
pants recruited into this study. Participants completed both the descriptive EQ-5D-3L system
and the accompanying visual analogue scale (VAS). We derived the EQ-5D utility scores using
the Zimbabwean EQ-5D tariff set [24], and report participants’ responses to the visual ana-
logue scale (VAS). The Zimbabwean tariff set generates utility scores ranging between -0.145
and 1.0, with 1.0 corresponding to “perfect health” and 0 representing a health state considered
to be equivalent to death. The visual analogue scale is similar to a thermometer, and ranges
from 100 (best imaginable health state) to 0 (worst imaginable health state). S3 Text provides a
detailed description of procedures used.
Statistical analysis
All analyses were undertaken in Stata version 13.1 (Stata Corporation, Texas, USA) and R ver-
sion is 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). All costs were con-
verted into 2014 US Dollars using market exchange rates and International Dollars using
purchasing power parity conversion factors [25, 26]. Principal component analysis was used to
generate wealth quintiles by combining socioeconomic variables, which included nine house-
hold assets, and home environment variables [27]. The discharge medical diagnosis was coded
as the highest level of the four-level ICD-9-CM recorded by the study doctors. Where there
Costs and QoL outcomes of hospitalisation
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were fewer than four participants with the same discharge medical diagnosis, the diagnosis
was based upon the next highest level of the four-level ICD-9-CM code recorded by the study
doctors.
We estimated the total direct health provider cost, total direct non-medical and indirect
cost and total societal cost according to each participant’s discharge medical diagnosis. The
total societal cost per participant was estimated by summing the total direct health provider
cost, and the total direct non-medical and indirect cost (the latter calculated by summing dura-
tion weighted cost estimates from each of the cost assessments). For each of these three cost
categories we investigated differences, firstly by HIV status, and secondly by whether or not
the participant was on ART at the time of admission. As the cost data was skewed, we used
non-parametric bootstrap methods with 1000 bootstrap replications to derive 95% confidence
intervals (CI) for mean cost differences for relevant cost categories [28]. In addition, we under-
took multivariable analysis to investigate the independent effects of HIV and ART status on
these costs. As all participants incurred a cost, and cost data was skewed, we used generalized
linear models (GLM) for multivariable analyses of cost data [29]. We ran model diagnostics to
determine the optimal choices for the distributional family and link function for these GLM
models [30].
For HRQoL assessments, we estimated the EQ-5D utility and VAS scores on admission, on
discharge and the change in scores. For the discharge EQ-5D utility score and VAS score, we
used the last recorded assessment, and attributed a value of zero for those who died in hospital
[31].
We investigated differences in the admission EQ-5D utility and VAS scores by HIV status,
and for those who were HIV-positive, by whether or not they were taking ART on admission.
In addition, we constructed multivariable models to investigate the independent effects of HIV
and ART status on HRQoL assessment on admission. EQ-5D utility and VAS scores were
non-normally distributed, skewed and truncated. Therefore, we used non-parametric boot-
strap methods, with 1000 bootstrap replications, to derive 95% confidence intervals (CI) for
mean differences. For the multivariable analysis, we evaluated four commonly used estimators
to analyse these data: ordinary least squares (OLS) regression; Tobit regression, Fractional
logit regression, and censored least absolute deviations (CLAD) regression [32–34]. We com-
pared the mean squared error (MSE), mean absolute error (MAE) and the coefficient of deter-
mination (r2) statistics between the observed and estimated scores for the whole sample, and
for sub-groups of the sample to determine the choice of preferred estimator.
For all multivariable analyses of cost and HRQoL outcomes we ran two alternative models,
the first adjusted for HIV status, age and sex, and the second additionally adjusted for marital
status, educational attainment, income, socio-economic position and the discharge medical
diagnosis. We included the discharge medical diagnosis in these models as the aim was to inves-
tigate independent associations between HIV and ART status, and cost or HRQoL outcomes.
Sensitivity analysis
We undertook sensitivity analyses to investigate the impact of using an alternative tariff set to
determine EQ-5D utility scores. We used the UK York A1 tariff [35], which has been found to
translate health states with ‘severe’ problems in one or more of the five dimensions to lower
EQ-5D utility scores than the Zimbabwean tariff [24].
Results
During the study period 1,010 eligible participants were admitted to the QECH’s adult medical
wards (Fig 1). In total, 87 (8.7%) died and 30 (3.0%) left hospital or were discharged before
Costs and QoL outcomes of hospitalisation
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Fig 1. Recruitment of participants. Readmissions were coded as a separate admission.
https://doi.org/10.1371/journal.pone.0192991.g001
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recruitment was possible. Of the remaining 893 eligible participants, 805 (90.1%) consented to
participate, and medical notes were found for 647 (80.4%).
Table 1 shows the characteristics of participants by HIV status. Of the 647 participants
recruited into the study and for whom the medical notes were found, 134 (20.7%) died in hos-
pital. Overall, 447 (69.1%) were HIV-positive, and 25 (3.9%) had an unknown HIV status. Of
those who were HIV-positive, 339 (75.8%) were already on ART on admission. S1–S4 Tables
details the health provider per diem cost for each of the three wards; unit costs per dosage of
drug dispensed through the QECH’s pharmacy department; and unit costs for investigations
and procedures performed.
Table 2 shows the participant characteristics, HIV status and outcomes by the 35 identified
discharge medical diagnoses. The three most common reasons for hospital admission were:
pneumonia (93/647; 14.4%); septicaemia (58/647; 9.0%); and pulmonary TB (54/647; 8.3%).
The mean duration of hospital admission amongst all participants was 12.0 days (95%CI:
11.0–13.1). The mean duration of admission for participants who were HIV-negative, HIV-
positive and not on ART, and HIV-positive on ART was 10.8 days (95%CI: 8.8–12.8), 15.0
days (95%CI: 12.0–18.0) and 12.2 days (95%CI: 10.8–13.7), respectively.
The mean total health provider cost per individual hospital admission, and the mean aver-
age daily cost, were US$313.65 (INT$788.83) and US$32.14 (INT$80.77), respectively
(Table 3). Ward costs accounted for 61.2%, investigations and medical procedures accounted
for 35.5%, and drugs accounted for 3.6% of the total International Dollar costs. The three dis-
charge medical diagnoses associated with the highest mean total health provider costs were:
cryptococcal meningitis (US$846.24); retreatment for TB (US$741.14); and TB of the menin-
ges and central nervous system (US$721.02) (Fig 2).
Table 4 shows the mean total direct non-medical and indirect costs, and the mean total
societal costs, for all participants by discharge medical diagnosis. The mean total direct non-
medical and indirect cost per hospital admission was US$87.84 (INT$243.99). The mean total
societal cost per hospital admission was US$401.48 (INT$1032.82). The three discharge medi-
cal diagnoses associated with the highest mean total societal costs were: TB of the meninges
and central nervous system (US$1228.38); cryptococcal meningitis (US$977.75); and retreat-
ment for TB (US$915.32).
The EQ-5D utility and VAS scores for all participants, and by discharge medical diagnosis,
are shown in Table 5. For all participants, the mean EQ-5D utility score and VAS score on
admission was 0.483 (SE: 0.01) and 52.8 (SE: 0.8), respectively (Table 5). The three discharge
medical diagnoses associated with the lowest EQ-5D utility scores on admission were TB of
the meninges and central nervous system, candidiasis and cerebrovascular disease (Fig 3). For
all participants, the mean change in EQ-5D utility and VAS scores was 0.020 (SE: 0.01) and 0.4
(SE: 1.2), respectively. The mean change in EQ-5D utility score, derived using the UK tariff
set, was 0.116 (SE: 0.02) (S5 Table).
Table 6 shows the costs for participants by their HIV status. The mean total provider cost of
admission for participants who were HIV-negative, HIV-positive and not on ART, and HIV-
positive on ART, was US$267.07, US$422.90 and US$316.03, respectively. The mean total pro-
vider cost of admission for HIV-positive participants was US$74.78 (bootstrap 95%CI: US
$25.41-US$124.15) higher than for HIV-negative participants. Amongst HIV-positive partici-
pants, the mean total provider cost was US$106.87 (bootstrap 95%CI: US$25.09-US$188.64)
lower for those already on ART on admission.
There were no significant differences in the mean total direct non-medical and indirect
cost by HIV or ART status. The mean total societal cost of hospital admission for participants
who were HIV-negative, HIV-positive and not on ART, and HIV-positive on ART, was US
$342.20, US$546.61 and US$404.65, respectively. The mean total societal cost of admission for
Costs and QoL outcomes of hospitalisation
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Table 1. Participant characteristics (n = 647).
HIV negative HIV positive HIV status unknown
n (%) n (%) n (%)
All 175 447 25
Sex Male 93 (53.1%) 230 (51.5%) 20 (80.0%)
Female 82 (46.9%) 217 (48.5%) 5 (20.0%)
Age group (years) 18–24 31 (17.7%) 38 (8.5%) 5 (20.0%)
25–34 36 (20.6%) 143 (32.0%) 3 (12.0%)
35–44 23 (13.1%) 156 (34.9%) 8 (32.0%)
45+ 84 (48.0%) 105 (23.5%) 9 (36.0%)
Missing 1 (0.6%) 5 (1.1%) 0 (0%)
Marital status Single (never-married) 28 (16.0%) 38 (8.5%) 5 (20.0%)
Married/cohabiting 101 (57.7%) 243 (54.4%) 10 (10.0%)
Separated/divorced 12 (6.9%) 85 (19.0%) 2 (8.0%)
Widower/widow 29 (16.6%) 59 (13.2%) 3 (12.0%)
Missing 5 (2.9%) 22 (4.9%) 5 (20.0%)
Educational attainment Up to standard 8 117 (66.9%) 233 (52.1%) 11 (44.0%)
Up to form 6 46 (26.3%) 182 (40.7%) 8 (32.0%)
University or training college 7 (4.0%) 10 (2.2%) 1 (4.0%)
Missing 5 (2.9%) 22 (4.9%) 5 (20.0%)
Income Not working 94 (53.7%) 183 (40.9%) 17 (68.0%)
Up to 4,000 kwacha/week 21 (12.0%) 62 (13.9%) 3 (12.0%)
4,000 to 8,000 kwacha/week 18 (10.3%) 59 (13.2%) 2 (8.0%)
8,000 to 12,000 kwacha/week 7 (4.0%) 32 (7.2%) 0 (0%)
Over 12,000 kwacha/week 33 (18.9%) 104 (23.3%) 3 (12.0%)
Missing 2 (1.1%) 7 (1.6%) 0 (0%)
Employment status Formal employment 31 (17.7%) 93 (20.8%) 4 (16.0%)
Informal employment/Unemployed 50 (28.6%) 161 (36.0%) 10 (40.0%)
School/University 14 (8.0%) 11 (2.5%) 4 (16.0%)
Retired 1 (0.6%) 3 (0.7%) 0 (0%)
Housework 68 (38.9%) 130 (29.1%) 7 (28.0%)
Sick leave 9 (5.1%) 43 (9.6%) 0 (0%)
Missing 2 (1.1%) 6 (1.3%) 0 (0%)
Socio-economic position Highest quintile 34 (19.4%) 90 (20.1%) 3 (12.0%)
2nd highest quintile 23 (13.1%) 92 (20.6%) 4 (16.0%)
Middle quintile 31 (17.7%) 90 (20.1%) 4 (16.0%)
2nd lowest quintile 34 (19.4%) 82 (18.3%) 3 (12.0%)
Lowest quintile 45 (25.7%) 67 (15.0%) 6 (24.0%)
Missing 8 (4.6%) 26 (5.8%) 5 (20.0%)
ART status Not on ART 108 (24.2%)
On ART 339 (75.8%)
Outcome Discharged home alive 151 (86.3%) 342 (76.5%) 20 (80.0%)
Died as inpatient 24 (13.7%) 105 (23.5%) 5 (20.0%)
ART: Anti-retroviral treatment
Up to Standard 8 equivalent to completing Primary school; Up to form 6 equivalent to completing Secondary/High school.
426 Malawian Kwacha = US$1 in 2014
Socio-economic position estimated though undertaking principal component analysis of responses to asset ownership and housing environment amongst
respondents
https://doi.org/10.1371/journal.pone.0192991.t001
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HIV-positive participants was US$96.76 (bootstrap 95%CI: US$17.11-US$176.40) higher than
for HIV-negative participants. Amongst HIV-positive participants, the mean total societal cost
of admission was US$141.95 (bootstrap 95%CI: US$24.73-US$259.17) lower for those already
on ART on admission.
The mean admission EQ-5D utility score for participants who were HIV-negative, HIV-
positive and not on ART, and HIV-positive on ART, was 0.532, 0.447 and 0.472, respectively
Table 2. Characteristics of participants by the discharge medical diagnosis (n = 647).
Discharge medical diagnosis n Sex Age HIV status Outcome Days of admission
Male (n/%) 45+ (n/%) HIV positive (n/%) On ART (n/%) Died (n/%) Mean (SE)
Pulmonary Tuberculosis 54 39 (72.2%) 10 (18.5%) 47 (87.0%) 34 (63.0%) 14 (25.9%) 23.9 (3.0)
Tuberculosis of the meninges and central nervous system 16 10 (62.5%) 5 (31.3%) 16 (100%) 11 (68.8%) 8 (50.0%) 38.3 (7.3)
Tuberculosis of intestines, peritoneum 9 6 (66.7%) 3 (33.3%) 7 (77.8%) 4 (44.4%) 3 (33.3%) 19.2 (5.6)
Tuberculosis of bones and joint 4 3 (75.0%) 3 (75.0%) 2 (50.0%) 2 (50.0%) 2 (50.0%) 19.0 (5.6)
Tuberculosis of other organs 15 10 (66.7%) 5 (33.3%) 12 (80.0%) 9 (60.0%) 7 (46.7%) 26.2 (8.6)
Miliary Tuberculosis 17 11 (64.7%) 4 (23.5%) 14 (82.4%) 12 (70.6%) 10 (58.8%) 10.7 (1.0)
Tuberculosis—retreatment 6 4 (66.7%) 1 (16.7%) 5 (83.3%) 5 (83.3%) 2 (33.3%) 41.2 (11.8)
Septicaemia 58 24 (41.4%) 13 (22.4%) 37 (63.8%) 30 (51.7%) 10 (17.2%) 8.4 (1.0)
Candidiasis 6 2 (33.3%) 1 (16.7%) 6 (100%) 5 (83.3%) 1 (16.7%) 5.7 (1.7)
Cryptococcal meningitis 36 27 (75.0%) 3 (8.3%) 36 (100%) 27 (75.0%) 9 (25.0%) 15.9 (1.8)
Viral infection 8 4 (50.0%) 1 (12.5%) 8 (100%) 6 (75.0%) 4 (50.0%) 15.3 (3.9)
Pneumocystis Jivorecii pneumonia 9 4 (44.4%) 1 (11.1%) 9 (100%) 3 (33.3%) 2 (22.2%) 13.4 (1.9)
Malaria 13 3 (23.1%) 3 (23.1%) 10 (76.9%) 6 (46.2%) 1 (7.7%) 5.2 (1.6)
Kaposi’s sarcoma 20 16 (80.0%) 2 (10.0%) 20 (100%) 17 (85.0%) 5 (25.0%) 9.1 (1.2)
Neoplasms—excluding Kaposi’s 7 4 (57.1%) 3 (42.9%) 3 (42.9%) 2 (28.6%) 1 (14.3%) 15.6 (2.1)
Diabetes mellitus without complications 5 0 (0.0%) 3 (60.0%) 0 (0%) 0 (0%) 0 (0%) 3.8 (1.2)
Diabetes mellitus with complications 9 5 (55.6%) 6 (66.7%) 1 (11.1%) 1 (11.1%) 0 (0%) 8.2 (1.2)
Anaemia 35 14 (40.0%) 11 (31.4%) 26 (74.3%) 24 (68.6%) 6 (17.1%) 9.4 (1.3)
Mental health disorders 9 6 (66.7%) 2 (22.2%) 2 (22.2%) 1 (11.1%) 0 (0%) 6.6 (1.9)
Meningitis 37 11 (29.7%) 11 (29.7%) 26 (70.3%) 19 (51.4%) 5 (13.5%) 9.2 (0.8)
Epilepsy; Convulsions 10 5 (50.0%) 2 (20.0%) 3 (30.0%) 3 (30.0%) 1 (10.0%) 6.3 (0.9)
Other neurological problems 16 12 (75.0%) 4 (25.0%) 8 (50.0%) 8 (50.0%) 1 (6.3%) 10.3 (2.6)
Cerebrovascular disease 25 12 (48.0%) 16 (64.0%) 10 (40.0%) 6 (24.0%) 2 (8.0%) 8.6 (1.1)
Hypertension 7 5 (71.4%) 5 (71.4%) 2 (28.6%) 1 (14.3%) 2 (28.6%) 11.1 (4.4)
Congestive heart failure; non-hypertensive 15 6 (40.0%) 12 (80.0%) 2 (13.3%) 0 (0.0%) 5 (33.3%) 9.4 (2.1)
Other cardiovascular problems 12 4 (33.3%) 8 (66.7%) 5 (41.7%) 4 (33.3%) 2 (16.7%) 10.2 (3.7)
Pneumonia 93 51 (54.8%) 23 (24.7%) 74 (79.6%) 56 (60.2%) 13 (14.0%) 7.5 (0.9)
Other respiratory problems 11 3 (27.3%) 6 (54.6%) 5 (45.5%) 4 (36.4%) 1 (9.1%) 9.9 (2.4)
Acute—Intestinal infection 10 10 (100%) 4 (40.0%) 6 (60.0%) 5 (50.0%) 1 (10.0%) 12.6 (3.5)
Chronic—Intestinal infection 14 5 (35.7%) 4 (28.6%) 11 (78.6%) 10 (71.4%) 4 (28.6%) 6.7 (1.4)
Upper gastrointestinal disorders 11 2 (18.2%) 4 (36.4%) 8 (72.7%) 7 (63.6%) 2 (18.2%) 5.7 (0.6)
Liver disease 14 8 (57.1%) 4 (28.6%) 9 (64.3%) 6 (42.9%) 6 (42.9%) 10.0 (1.9)
Diseases of the genitourinary system 18 7 (38.9%) 8 (44.4%) 14 (77.8%) 9 (50.0%) 3 (16.7%) 7.7 (1.3)
Diseases of the musculoskeletal system 6 5 (83.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 0 (0%) 15.0 (4.2)
Other problems (<5 cases) 12 5 (41.7%) 3 (25.0%) 1 (8.3%) 1 (8.3%) 1 (8.3%) 7.3 (0.9)
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Table 3. Total direct health provider costs by discharge medical diagnosis (n = 647).
Discharge medical diagnosis Total health provider cost Average daily cost Mean proportion of total heath provider cost
2014 US
Dollars
2014 INT
Dollars
2014 US
Dollars
2014 INT
Dollars
%
Drugs
% Investigations &
Procedures
% Ward
stay
N Mean (SE) Mean (SE) Mean (SE) Mean (SE)
All 647 313.65 (12.2) 788.83 (27.7) 32.14 (0.9) 80.77 (1.9) 3.6 35.5 61.2
Pulmonary tuberculosis 54 477.57 (51.5) 1252.59
(137.2)
23.67 (1.0) 61.11 (2.6) 3.4 26.2 70.8
Tuberculosis of the meninges and central
nervous system
16 721.02
(117.3)
1891.95
(306.6)
32.93 (5.7) 87.60 (15.5) 2.9 33.0 64.6
Tuberculosis of intestines, peritoneum 9 429.92 (97.2) 1119.28
(252.3)
26.24 (3.6) 68.23 (9.3) 3.1 29.3 67.9
Tuberculosis of bones and joint 4 376.51
(106.7)
1016.96
(288.9)
19.82 (0.9) 53.62 (2.03) 1.7 19.8 78.9
Tuberculosis of other organs 15 523.78
(138.1)
1386.15
(378.5)
25.95 (2.5) 66.52 (6.0) 3.6 29.1 67.6
Miliary tuberculosis 17 289.61 (25.5) 753.68 (66.9) 28.16 (1.9) 73.22 (4.8) 3.1 35.8 61.5
Tuberculosis—retreatment 6 741.14
(203.4)
1943.75
(535.0)
20.24 (2.1) 52.69 (5.4) 3.6 15.4 81.7
Septicaemia 58 222.13 (18.0) 580.97 (47.3) 33.71 (2.3) 87.84 (6.0) 2.4 40.4 57.5
Candidiasis 6 153.08 (43.1) 395.98 (113.9) 31.12 (6.0) 77.70 (11.9) 2.8 35.5 62.2
Cryptococcal meningitis 36 846.24
(101.9)
1583.26
(138.6)
64.26 (9.5) 114.49 (10.9) 20.9 32.6 46.8
Viral infection 8 300.80 (70.1) 808.37 (192.2) 25.34 (5.7) 66.71 (14.6) 1.8 21.4 77.4
Pneumocystis Jivorecii pneumonia 9 325.56 (28.3) 849.35 (75.5) 26.79 (3.0) 69.55 (7.6) 2.9 29.9 67.3
Malaria 13 179.01 (36.0) 439.87 (94.3) 44.78 (6.7) 106.46 (14.4) 7.2 44.2 48.8
Kaposi’s sarcoma 20 230.99 (25.8) 609.69 (69.4) 28.99 (2.7) 75.55 (6.7) 2.5 35.5 62.5
Neoplasms—excluding Kaposi’s 7 320.31 (36.8) 839.86 (99.2) 21.08 (0.8) 54.88 (1.5) 2.6 19.1 78.4
Diabetes mellitus without complications 5 158.72 (40.3) 403.59 (106.2) 46.07 (8.6) 116.25 (20.7) 5.5 50.7 43.8
Diabetes mellitus with complications 9 217.13 (31.1) 574.67 (82.3) 30.54 (4.6) 80.10 (11.4) 3.1 36.7 60.2
Anaemia 35 251.79 (25.8) 678.01 (70.9) 33.43 (4.1) 89.61 (11.5) 1.7 39.7 58.9
Mental health disorders 9 186.64 (38.4) 496.94 (103.3) 33.14 (4.2) 87.91 (10.8) 2.0 44.5 53.5
Meningitis 37 250.76 (17.8) 646.86 (45.9) 30.76 (1.8) 79.23 (4.6) 3.2 37.2 59.9
Epilepsy; Convulsions 10 195.01 (17.1) 501.68 (44.4) 34.84 (3.9) 88.86 (8.9) 2.6 44.5 53.0
Other neurological problems 16 261.58 (48.6) 682.28 (127.9) 32.85 (3.3) 86.00 (8.5) 1.5 42.1 56.6
Cerebrovascular disease 25 207.26 (25.2) 551.48 (64.5) 26.66 (1.6) 71.18 (4.2) 1.9 32.5 65.8
Hypertension 7 234.21 (79.1) 633.97 (212.2) 25.47 (3.6) 68.18 (8.6) 1.7 31.6 66.8
Congestive heart failure; non-hypertensive 15 239.51 (47.6) 646.48 (132.4) 27.82 (2.7) 74.61 (7.3) 1.4 33.4 65.2
Other cardiovascular problems 12 269.03 (81.0) 702.02 (205.2) 29.99 (2.3) 79.42 (6.0) 2.7 38.4 59.1
Pneumonia 93 198.77 (14.4) 517.30 (39.4) 30.81 (0.9) 79.04 (2.2) 2.2 39.7 58.4
Other respiratory problems 11 242.98 (56.0) 641.18 (148.1) 25.93 (2.2) 68.01 (5.3) 2.6 29.5 68.1
Acute—Intestinal infection 10 250.82 (53.1) 667.67 (147.6) 23.10 (1.8) 60.53 (4.6) 3.3 23.7 73.5
Chronic—Intestinal infection 14 249.26 (61.0) 658.73 (166.3) 50.21 (18.8) 133.16 (52.0) 2.7 43.5 54.3
Upper gastrointestinal disorders 11 193.04 (46.0) 508.40 (129.3) 32.93 (5.0) 86.30 (14.1) 2.2 39.2 59.0
Liver disease 14 345.84
(103.9)
940.74 (287.6) 31.82 (3.2) 85.74 (8.8) 1.4 42.7 56.1
Diseases of the genitourinary system 18 202.25 (24.5) 537.57 (67.0) 29.02 (1.7) 76.68 (4.2) 2.1 38.1 60.1
Diseases of the musculoskeletal system 6 332.33 (79.2) 875.32 (203.1) 23.59 (1.4) 62.42 (3.9) 1.9 28.1 70.1
Other problems (<5 cases) 12 179.93 (23.3) 477.10 (58.2) 25.13 (1.5) 66.92 (3.6) 1.9 30.6 67.6
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(Table 6). The mean admission EQ-5D utility score amongst HIV-negative participants was
0.066 (bootstrap 95%CI: 0.019–0.114) higher than for HIV-positive participants. There were
no significant differences in the admission EQ-5D utility scores between HIV-positive partici-
pants who were on or not on ART.
Fig 2. Mean total costs by discharge medical diagnosis.
Except in Labour
Except that caused by TB or Cryptococcal
Total societal cost equates to the total direct health provider cost plus the total direct non-medical and indirect cost.
https://doi.org/10.1371/journal.pone.0192991.g002
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In the multivariable analysis (Model 1; Table 7), after adjusting for participant characteris-
tics and discharge medical diagnosis, the mean total provider costs of hospital admission was
US$51.04 (95%CI: US$7.23-US$94.86) lower for those who were HIV-positive and on ART on
admission compared to those who were HIV-positive and not on ART. There was no signifi-
cant difference in the mean total provider costs between HIV-negative individuals and HIV-
Table 4. Total direct non-medical and indirect, and societal costs by discharge medical diagnosis (n = 647).
Discharge medical diagnosis Total direct non-medical and indirect cost Total societal cost
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars
N Mean (SE) Mean (SE) Mean (SE) Mean (SE)
All 647 87.84 (10.2) 243.99 (28.3) 401.48 (18.8) 1032.82 (48.1)
Pulmonary tuberculosis 54 135.59 (29.7) 376.64 (82.5) 613.16 (68.6) 1629.23 (185.1)
Tuberculosis of the meninges and central nervous system 16 507.36 (205.6) 1409.33 (571.0) 1228.38 (284.7) 3301.29 (771.2)
Tuberculosis of intestines, peritoneum 9 424.13 (336.4) 1178.14 (934.4) 854.05 (431.0) 2297.42 (1179.0)
Tuberculosis of bones and joint 4 90.43 (34.9) 251.20 (97.1) 466.94 (134.3) 1268.16 (365.8)
Tuberculosis of other organs 15 299.43 (189.7) 831.74 (526.9) 823.21 (318.7) 2217.89 (882.0)
Miliary tuberculosis 17 48.55 (12.6) 134.86 (34.9) 338.16 (30.3) 888.54 (80.2)
Tuberculosis—retreatment 6 174.18 (130.8) 483.83 (363.4) 915.32 (280.4) 2427.58 (744.8)
Septicaemia 58 38.05 (8.2) 105.68 (22.9) 260.17 (24.2) 686.65 (64.6)
Candidiasis 6 25.86 (20.0) 71.84 (55.6) 178.94 (58.8) 467.81 (156.7)
Cryptococcal meningitis 36 131.50 (44.1) 365.28 (122.4) 977.75 (113.6) 1948.54 (206.2)
Viral infection 8 61.51 (32.9) 170.87 (91.4) 362.32 (89.5) 979.24 (245.7)
Pneumocystis Jivorecii pneumonia 9 69.59 (28.2) 193.30 (78.2) 395.15 (50.6) 1042.65 (139.6)
Malaria 13 124.91 (116.9) 346.97 (324.7) 303.92 (119.3) 786.85 (328.1)
Kaposi’s sarcoma 20 81.66 (21.5) 226.84 (59.6) 312.65 (43.2) 836.53 (118.3)
Neoplasms—excluding Kaposi’s 7 49.03 (15.6) 136.19 (43.3) 369.34 (45.8) 976.06 (126.0)
Diabetes mellitus without complications 5 21.63 (10.6) 60.07 (29.6) 180.34 (48.8) 463.66 (129.9)
Diabetes mellitus with complications 9 220.34 (145.4) 612.05 (404.0) 437.47 (157.4) 1186.72 (435.9)
Anaemia 35 57.20 (10.5) 158.90 (29.2) 308.99 (33.0) 836.91 (90.9)
Mental health disorders 9 72.97 (30.3) 202.69 (84.1) 259.61 (53.0) 699.64 (142.8)
Meningitis 37 49.54 (10.3) 137.61 (28.7) 300.30 (23.1) 784.47 (61.4)
Epilepsy; Convulsions 10 30.86 (19.8) 85.71 (55.0) 225.86 (27.9) 587.39 (75.7)
Other neurological problems 16 31.98 (9.3) 88.84 (25.9) 293.56 (56.1) 771.12 (149.1)
Cerebrovascular disease 25 42.98 (13.6) 119.39 (37.7) 250.24 (34.4) 670.87 (89.6)
Hypertension 7 46.52 (24.1) 129.23 (66.9) 280.73 (102.3) 763.20 (276.4)
Congestive heart failure; non-hypertensive 15 28.02 (7.3) 77.83 (20.2) 267.53 (49.3) 724.31 (136.6)
Other cardiovascular problems 12 44.31 (16.6) 123.08 (46.0) 313.34 (93.1) 825.10 (239.4)
Pneumonia 93 33.36 (5.6) 92.65 (15.6) 232.12 (19.0) 609.95 (52.4)
Other respiratory problems 11 46.70 (18.5) 129.71 (51.4) 289.67 (59.7) 770.89 (158.8)
Acute—Intestinal infection 10 155.70 (53.4) 432.49 (148.3) 406.52 (94.4) 1100.17 (262.8)
Chronic—Intestinal infection 14 26.29 (9.6) 73.03 (26.7) 275.55 (64.2) 731.76 (175.5)
Upper gastrointestinal disorders 11 68.22 (41.2) 189.49 (114.5) 261.26 (58.0) 697.89 (162.8)
Liver disease 14 56.37 (24.4) 156.57 (67.7) 402.21 (104.1) 1097.31 (288.1)
Diseases of the genitourinary system 18 39.71 (13.3) 110.31 (37.0) 241.96 (30.3) 647.87 (82.4)
Diseases of the musculoskeletal system 6 158.44 (93.6) 440.11 (260.1) 490.77 (111.2) 1315.43 (301.6)
Other problems (<5 cases) 12 44.46 (16.4) 123.50 (45.6) 224.39 (34.0) 600.60 (86.8)
Except in Labour
Except that caused by TB or Cryptococcal
https://doi.org/10.1371/journal.pone.0192991.t004
Costs and QoL outcomes of hospitalisation
PLOS ONE | https://doi.org/10.1371/journal.pone.0192991 March 15, 2018 12 / 21
positive individuals not on ART on admission. After adjusting for discharge medical diagnosis
(Model 2), we did not find any significant differences in either mean total direct non-medical
and indirect costs or mean total societal costs by HIV or ART status.
The findings of the multivariable analysis exploring the relationship between HIV status
and the EQ-5D utility scores on admission are shown in Table 8. In the multivariable analysis,
Table 5. Health-related quality of life outcomes by discharge medical diagnosis (n = 640).
Discharge medical diagnosis N EQ-5D utility scores (Zimbabwean tariff) VAS scores
On admission Last recorded Change On admission Last recorded Change
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
All 640 0.483 (0.01) 0.503 (0.01) +0.020 (0.01) 52.8 (0.8) 53.2 (1.3) +0.4 (1.2)
Pulmonary tuberculosis 54 0.445 (0.04) 0.486 (0.05) +0.041 (0.04) 55.1 (3.0) 55.4 (5.0) +0.2 (4.4)
Tuberculosis of the meninges and central nervous system 16 0.275 (0.08) 0.304 (0.09) +0.030 (0.12) 41.3 (7.2) 37.4 (10.1) -3.9 (8.6)
Tuberculosis of intestines, peritoneum 9 0.524 (0.11) 0.430 (0.11) -0.094 (0.07) 50.0 (7.5) 42.2 (12.1) -7.8 (11.4)
Tuberculosis of bones and joint 4 0.379 (0.12) 0.277 (0.16) -0.101 (0.10) 65.0 (9.6) 45.0 (26.3) -20.0 (17.3)
Tuberculosis of other organs 15 0.542 (0.08) 0.376 (0.10) -0.166 (0.10) 51.0 (6.1) 41.3 (10.7) -9.7 (10.5)
Miliary tuberculosis 17 0.393 (0.07) 0.185 (0.07) -0.208 (0.07) 38.5 (4.4) 20.9 (7.5) -17.6 (8.2)
Tuberculosis—retreatment 6 0.577 (0.15) 0.545 (0.17) -0.032 (0.08) 73.3 (7.6) 54.2 (17.6) -19.2 (19.0)
Septicaemia 58 0.512 (0.04) 0.577 (0.04) +0.064 (0.04) 53.0 (2.9) 55.2 (4.2) +2.1 (3.8)
Candidiasis 6 0.349 (0.09) 0.424 (0.10) +0.074 (0.08) 48.3 (11.7) 50.0 (11.8) +1.7 (1.7)
Cryptococcal meningitis 36 0.478 (0.04) 0.474 (0.06) -0.004 (0.06) 56.4 (3.3) 52.2 (5.6) -4.1 (6.1)
Viral infection 8 0.589 (0.10) 0.395 (0.15) -0.195 (0.12) 56.3 (9.8) 41.9 (15.9) -14.4 (12.2)
Pneumocystis Jivorecii pneumonia 8 0.559 (0.08) 0.501 (0.15) -0.058 (0.16) 55.0 (8.0) 58.8 (13.3) +3.8 (11.0)
Malaria 13 0.521 (0.07) 0.514 (0.08) -0.006 (0.03) 53.2 (6.6) 53.9 (6.5) +0.8 (11.0)
Kaposi’s sarcoma 20 0.415 (0.06) 0.402 (0.06) -0.014 (0.05) 48.3 (3.5) 46.5 (7.2) +0.8 (1.4)
Neoplasms—excluding Kaposi’s 7 0.567 (0.08) 0.342 (0.15) -0.225 (0.13) 52.9 (5.2) 42.1 (11.0) -10.7 (12.8)
Diabetes mellitus without complications 5 0.682 (0.06) 0.815 (0.05) +0.133 (0.08) 73.4 (8.1) 80.4 (9.0) +7.0 (3.7)
Diabetes mellitus with complications 9 0.405 (0.09) 0.443 (0.09) +0.038 (0.07) 54.4 (3.4) 57.2 (5.7) +2.8 (3.6)
Anaemia 35 0.558 (0.04) 0.586 (0.06) +0.028 (0.05) 52.5 (3.2) 59.4 (5.4) +7.0 (5.3)
Mental health disorders 9 0.629 (0.08) 0.705 (0.07) +0.076 (0.09) 61.1 (4.8) 67.2 (6.1) +6.1 (4.2)
Meningitis 36 0.484 (0.04) 0.611 (0.05) +0.126 (0.05) 49.9 (3.5) 59.3 (4.8) +9.4 (3.8)
Epilepsy; Convulsions 10 0.561 (0.12) 0.560 (0.14) -0.002 (0.05) 57.0 (6.3) 64.0 (8.7) +7.0 (5.0)
Other neurological problems 15 0.506 (0.06) 0.524 (0.07) +0.018 (0.06) 55.3 (4.1) 57.5 (6.8) +2.2 (5.7)
Cerebrovascular disease 23 0.359 (0.05) 0.438 (0.07) +0.078 (0.04) 50.7 (4.9) 54.3 (5.3) +3.7 (5.5)
Hypertension 7 0.387 (0.13) 0.419 (0.14) +0.032 (0.11) 58.6 (2.6) 50.7 (13.8) -7.9 (15.9)
Congestive heart failure; non-hypertensive 15 0.569 (0.06) 0.476 (0.10) -0.092 (0.09) 57.0 (4.8) 49.7 (10.1) -7.3 (10.6)
Other cardiovascular problems 12 0.500 (0.08) 0.613 (0.09) +0.113 (0.11) 55.0 (4.8) 59.2 (9.2) +4.2 (7.9)
Pneumonia 91 0.501 (0.03) 0.553 (0.03) +0.053 (0.03) 53.3 (2.4) 56.4 (3.4) +3.2 (2.8)
Other respiratory problems 11 0.486 (0.08) 0.681 (0.09) +0.195 (0.09) 50.5 (5.7) 58.6 (7.5) +8.2 (8.3)
Acute—Intestinal infection 10 0.487 (0.10) 0.516 (0.09) +0.029 (0.10) 56.0 (7.3) 48.0 (6.3) -8.0 (11.2)
Chronic—Intestinal infection 14 0.434 (0.08) 0.400 (0.09) -0.035 (0.10) 50.0 (2.5) 42.9 (8.4) -7.1 (8.2)
Upper gastrointestinal disorders 11 0.501 (0.06) 0.485 (0.10) -0.015 (0.10) 52.5 (3.7) 57.4 (9.9) +4.9 (10.5)
Liver disease 14 0.436 (0.09) 0.405 (0.10) -0.032 (0.07) 45.0 (5.9 41.4 (10.3) -3.6 (8.4)
Diseases of the genitourinary system 18 0.538 (0.06) 0.584 (0.09) +0.047 (0.08) 53.3 (4.9 59.7 (7.5) +6.4 (7.1)
Diseases of the musculoskeletal system 6 0.416 (0.09) 0.338 (0.11) -0.078 (0.12) 47.5 (4.4) 61.7 (6.0) +14.2 (7.8)
Other problems (<5 cases) 12 0.431 (0.07) 0.542 (0.08) +0.112 (0.09) 52.5 (3.9) 57.9 (7.2) +5.4 (7.5)
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the model diagnostics showed that the OLS estimator performed as well or better than the
other estimators (S6 and S7 Tables). In the multivariable analysis, after adjusting for individual
characteristics and the discharge medical diagnosis, the mean admission EQ-5D utility score
amongst those who were HIV-negative was 0.131 (95%CI: 0.064–0.198) higher than amongst
those who were HIV-positive and not on ART on admission. There were no significant differ-
ences in the adjusted EQ-5D utility scores between those who were HIV-positive and either
taking or not taking ART on admission.
Discussion
The main findings of this study are the high costs incurred in managing adults admitted to
hospital in a resource-poor setting with high HIV prevalence. Health provider costs were espe-
cially high for managing HIV-associated illnesses. However, costs were substantially lower,
with significantly shorter duration of admission and less risk of death, if individuals were
Fig 3. Frequency, distribution and density of EQ-5D utility scores by medical diagnosis. Except in Labour
Except that caused by TB or Cryptococcal.
https://doi.org/10.1371/journal.pone.0192991.g003
Costs and QoL outcomes of hospitalisation
PLOS ONE | https://doi.org/10.1371/journal.pone.0192991 March 15, 2018 14 / 21
already receiving ART on hospital admission. Health-related quality of life was especially poor
amongst those admitted for HIV-associated illnesses, and overall, was significantly lower in
HIV-positive than HIV-negative participants. Our data also highlights the substantial burden
imposed on the finances of patients and their families as a result of hospitalisation. Even
though patients do not pay for medical services, the mean cost from the patient perspective
was US$87.84, amounting to catastrophic costs for most patients.
In this study, the average health provider cost of managing individuals in hospital was US
$313.65, with substantially higher costs for HIV-positive individuals and for AIDS-defining
diseases. Total provider costs of one year of ART have been estimated to be US$136 (in 2011
prices) in Malawi [36]. HIV-positive individuals will continue to be at increased risk of hospi-
talisation after initiation of ART, especially if treatment is started late, but at a population level,
timely ART initiation will reduce the absolute numbers requiring admission [37]. Moreover,
the substantial cost differences found between those taking and not taking ART in this study
raise the prospect of considerably higher savings from ART than would be anticipated on the
basis of admission rates alone. This difference remained even after accounting for differences
in cause of admission. Thus, the costs incurred in providing early initiation of ART to greater
numbers of people living with HIV may be offset by larger cost savings than have been
Table 6. Costs and health-related quality of life outcomes by HIV status.
Mean differences (95% CI)
N Mean (SE) HIV-positive v HIV-negative On ART v Not on ART
Total health provider cost (2014 US$) HIV-negative 175 267.07 (20.2) 74.78 (25.41, 124.15) -106.87 (-188.64, -25.09)
HIV-positive: not on ART 108 422.90 (40.4)
HIV-positive: on ART 339 316.03 (15.7)
HIV status unknown 25 135.42 (19.7)
Total direct non-medical and indirect cost (2014 US$) HIV-negative 175 75.12 (18.7) 21.98 (-21.36, 65.32) -35.09 (-98.84, 28.66)
HIV-positive: not on ART 108 123.71 (30.1)
HIV-positive: on ART 339 88.62 (13.8)
HIV status unknown 25 11.14 (5.3)
Total societal cost (2014 US$) HIV-negative 175 342.20 (34.0) 96.76 (17.11, 176.40) -141.95 (-259.17, -24.73)
HIV-positive: not on ART 108 546.61 (56.0)
HIV-positive: on ART 339 404.65 (25.1)
HIV status unknown 25 146.55 (21.3)
Admission EQ-5D utility score (Zimbabwean tariff) HIV-negative 174 0.532 (0.02) -0.066 (-0.114, -0.019) 0.025 (-0.033, 0.082)
HIV-positive: not on ART 107 0.447 (0.03)
HIV-positive: on ART 336 0.472 (0.02)
HIV status unknown 23 0.454 (0.07)
Admission VAS score HIV-negative 174 55.1 (1.4) -3.2 (-6.7, 0.2) -2.2 (-7.0, 2.5)
HIV-positive: not on ART 107 53.5 (2.1)
HIV-positive: on ART 336 51.3 (1.1)
HIV status unknown 23 53.9 (5.8)
Admission EQ-5D utility score (UK tariff) HIV-negative 174 0.335 (0.03) -0.096 (-0.165, -0.027) 0.058 (-0.022, 0.138)
HIV-positive: not on ART 107 0.195 (0.03)
HIV-positive: on ART 336 0.253 (0.02)
HIV status unknown 23 0.280 (0.09)
ART: Anti-retroviral treatment
Missing quality of life assessment—HIV negative: 1; HIV positive not on ART: 1; HIV positive on ART: 3; HIV status unknown: 2
Bootstrapped estimates of mean differences and 95%CI
https://doi.org/10.1371/journal.pone.0192991.t006
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appreciated. Importantly, we found that the majority of patients were aware of their HIV sta-
tus, and many of those who were HIV-positive had already started ART. In the study we were
unable to ascertain the stage of participants’ HIV infection, or when ART was initiated.
In Malawi, hospital care is provided free but users inevitably incur some costs in accessing
care, including for transportation to and from hospital, and losses in income. The mean direct
non-medical and indirect cost was estimated at US$86.93. The majority of Malawians live on
less than $2 a day [38], highlighting the catastrophic impact of a hospitalisation on the finances
of Malawians. Whilst preventing illness will have a major impact on reducing this burden,
offering social security benefits to those affected needs to be explored further [39].
Tuberculosis continues to be one of the most common reasons for medical inpatient care in
sub-Saharan Africa [1]. As in previous studies and surveillance data, the majority of TB
patients in our study were HIV positive. Individuals with HIV and TB coinfection reported
very poor HRQoL, with hospitalisation resulting in substantial costs for them and for the
Table 7. Multivariate analysis exploring relationship between HIV and ART status and mean total costs.
Total health provider cost (2014 US Dollars) Total direct non-medical and indirect cost
(2014 US Dollars)
Total societal cost (2014 US Dollars)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
HIV-positive: not
on ART
Ref Ref Ref Ref Ref Ref
HIV-positive: on
ART
-87.06 (-163.07,
-11.06)
-51.04 (-94.86,
-7.23)
15.00 (-25.27, 55.26) 18.92 (-23.65, 61.49) -70.98 (-159.24, 17.27) -45.99 (-99.88, 7.91)
HIV-negative -140.43 (-219.41,
-61.44)
-45.60 (-95.65, 4.45) -3.14 (-56.17, 49.88) 24.19 (-36.02, 84.40) -128.65 (-224.49,
-32.82)
-34.76 (-99.64, 30.11)
HIV status
unknown
-279.86 (-361.81,
-197.91)
-146.93 (-202.61,
-91.26)
-60.23 (-111.56,
-8.90)
-9.10 (-68.68, 50.49) -301.34 (-401.06,
-201.63)
-160.95 (-235.91,
-85.99)
ART: Anti-retroviral treatment
Model 1: age and sex
Model 2: additionally adjusted for primary medical diagnosis, marital status, educational attainment, income and wealth quintile
Findings from Generalized linear model with Poisson distribution and identity link function
 p<0.05
https://doi.org/10.1371/journal.pone.0192991.t007
Table 8. Multivariate analysis exploring relationship between HIV and ART status and health-related quality of life outcomes on admission.
Admission EQ-5D utility score (Zimbabwean
tariff)
Admission VAS score Admission EQ-5D utility score (UK tariff)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
Model 1 (n = 605)
Coef (95% CI)
Model 2 (n = 605)
Coef (95% CI)
HIV-positive: not
on ART
Ref Ref Ref Ref Ref Ref
HIV-positive: on
ART
0.038 (-0.019, 0.095) 0.048 (-0.011, 0.106) -0.99 (-5.23, 3.25) -0.55 (-4.80, 3.69) 0.070 (-0.013, 0.152) 0.085 (-0.001, 0.170)
HIV-negative 0.112 (0.051, 0.173) 0.131 (0.064, 0.198) 2.92 (-1.63, 7.47) 3.20 (-1.60, 7.99) 0.185 (0.095, 0.275) 0.207 (0.108, 0.306)
HIV status
unknown
0.076 (-0.066, 0.218) 0.092 (-0.062, 0.245) 7.85 (-0.85, 16.54) 9.47 (-0.07, 19.01) 0.147 (-0.062, 0.356) 0.160(-0.065, 0.385)
Model 1: age and sex
Model 2: additionally adjusted for primary medical diagnosis, marital status, educational attainment, income and wealth quintile
Findings from ordinary least squares estimator
 p<0.05
https://doi.org/10.1371/journal.pone.0192991.t008
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health system. Hospitalisation may be unavoidable for some TB patients, considering the
severity of their illness, but moving the later stages of care to community-based TB services,
which are already established in much of the region, could reduce these costs [40]. Rapid scale
up TB preventive therapy and systematic TB screening on all health encounters are urgently
required [41].
The World Health Organization’s (WHO) prequalification of medicines programme
ensures high quality drugs enter African healthcare markets at reasonable prices [42]. In our
study, we found drugs accounted for a lower proportion of total health provider costs than
investigations and procedures. The WHO prequalification programme does extend to diag-
nostics and medical devices; however, the focus has predominantly been around rapid diag-
nostic and point of care tests. Extending these services to all medical consumables and
equipment may reduce costs, and facilitate decentralisation of diagnostic services to district
level hospitals.
We used the EuroQol EQ-5D measure to provide two assessments of HRQoL, including
one (EQ-5D utility score) that can be used to inform cost-utility analyses. The mean EQ-5D
utility score reported was 0.498, with HIV-positive inpatients reporting much lower HRQoL
than HIV-negative inpatients. The mean EQ-5D utility score amongst HIV-positive inpatients
who had not started ART (0.447) was considerably lower than reported by HIV-positive out-
patients in the catchment population of this hospital (0.8) [21]. This further reinforces the
value of early diagnosis and ART initiation to prevent serious and debilitating illness, and
maintenance of HRQoL. Of concern were the minimal changes in HRQoL outcomes during
admission, although this has to be interpreted in the context of high inpatient mortality.
Health utility data are notably lacking in this region, constraining the use of cost-utility analy-
ses in economic evaluations [43, 44]. This study provides an extensive catalogue of health util-
ity scores, including those derived using an alternative tariff set (UK York A1), to inform cost-
utility analyses for a range of interventions, not just limited to HIV.
Study limitations include the relatively small number of participants recruited for a few of
the medical conditions; discharge medical diagnoses based on the assessment of one medical
doctor; and the fact the study was undertaken in a large central teaching hospital that limits
generalisability to smaller district hospital settings. In addition, we were unable to examine
economic outcomes in the sickest group of patients, those who died before recruitment was
possible, or whose medical notes were not found. However, this is the first study we are aware
of that estimates economic costs and HRQoL outcomes amongst a cohort of adults admitted
to hospital for medical reasons in an African context with high HIV prevalence. We collected
individual-level data on healthcare resources used, direct non-medical and indirect costs
incurred, and examined HRQoL outcomes. We undertook a primary costing study to estimate
the costs of all healthcare resources used, and provide estimates of the total health provider
costs.
Our findings highlight the catastrophic costs and poor HRQoL outcomes associated with
hospitalisation in a sub-Saharan cohort with high HIV prevalence. Importantly, as countries in
sub-Saharan Africa move towards immediate initiation of ART treatment for people living
with HIV, policy makers will need to be aware of the potential for substantial cost savings
from averting serious HIV-associated illnesses and through earlier case detection of
tuberculosis.
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